Combined with knowledge of decreased IL-1β production, smaller infarct volumes, and improved functional outcome, this information helps to understand how BM cells promote neuroprotection after tMCAo in mice, a potential future stroke therapy. This evidence concerns the gene IL1B and stroke disorder.